Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models

被引：36

作者：

Capello, Michela ^{[1
,2
]}

Cappello, Paola ^{[1
,2
]}

Linty, Federica Caterina ^{[1
,2
]}

Chiarle, Roberto ^{[1
]}

Sperduti, Isabella ^{[3
]}

Novarino, Anna ^{[4
]}

Salacone, Paola ^{[5
]}

Mandili, Giorgia ^{[1
,2
]}

Naccarati, Alessio ^{[6
]}

Sacerdote, Carlotta ^{[6
,7
,8
]}

Beghelli, Stefania ^{[9
]}

Bersani, Samantha ^{[10
]}

Barbi, Stefano ^{[10
]}

Bassi, Claudio ^{[11
]}

Scarpa, Aldo ^{[9
,10
]}

Nistio, Paola ^{[12
]}

Giovarelli, Mirella ^{[1
,2
]}

Vineis, Paolo ^{[6
,13
]}

Milella, Michele ^{[14
]}

Novelli, Francesco ^{[1
,2
]}

机构：

[1] Azienda Osped Citta Salute & Sci Torino, Ctr Expt Res & Med Studies CeRMS, Turin, Italy

[2] Univ Turin, Dept Mol Biotechnol & Life Sci, Turin, Italy

[3] Regina Elena Inst Canc Res, Div Biostat, Rome, Italy

[4] Azienda Osped Citta Salute & Sci Torino, Ctr Oncol Ematol Subalpino, Turin, Italy

[5] Ordine Mauriziano Hosp, Gastroenterol Unit, Turin, Italy

[6] HuGeF, Human Genet Fdn, Turin, Italy

[7] Univ Turin, Canc Epidemiol Unit, Turin, Italy

[8] Ctr Canc Epidemiol & Prevent CPO Piemonte, Turin, Italy

[9] Univ Verona, ARC NET Res Ctr, I-37100 Verona, Italy

[10] Univ Verona, Dept Pathol & Diagnost, I-37100 Verona, Italy

[11] Univ Verona, Dept Surg & Oncol, I-37100 Verona, Italy

[12] Regina Elena Inst Canc Res, Div Immunol, Rome, Italy

[13] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Epigenet Unit, London, England

[14] Regina Elena Inst Canc Res, Div Med Oncol, Rome, Italy

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2013年 / 6卷

关键词：

Pancreatic ductal adenocarcinoma; Tumor antigen; Genetically engineered mouse model; Early diagnosis; Ezrin; DUCTAL ADENOCARCINOMA; BREAST-CANCER; MOLECULES; PROTEINS; MARKERS;

D O I：

10.1186/1756-8722-6-67

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive malignancy with only a 5% 5-year survival rate. Reliable biomarkers for early detection are still lacking. The goals of this study were (a) to identify early humoral responses in genetically engineered mice (GEM) spontaneously developing PDAC; and (b) to test their diagnostic/predictive value in newly diagnosed PDAC patients and in prediagnostic sera. Methods and results: The serum reactivity of GEM from inception to invasive cancer, and in resectable or advanced human PDAC was tested by two-dimensional electrophoresis Western blot against proteins from murine and human PDAC cell lines, respectively. A common mouse-to-human autoantibody signature, directed against six antigens identified by MALDI-TOF mass spectrometry, was determined. Of the six antigens, Ezrin displayed the highest frequency of autoantibodies in GEM with early disease and in PDAC patients with resectable disease. The diagnostic value of Ezrin-autoantibodies to discriminate PDAC from controls was further shown by ELISA and ROC analyses (P < 0.0001). This observation was confirmed in prediagnostic sera from the EPIC prospective study in patients who eventually developed PDAC (with a mean time lag of 61.2 months between blood drawing and PDAC diagnosis). A combination of Ezrin-autoantibodies with CA19.9 serum levels and phosphorylated alpha-Enolase autoantibodies showed an overall diagnostic accuracy of 0.96 +/- 0.02. Conclusions: Autoantibodies against Ezrin are induced early in PDAC and their combination with other serological markers may provide a predictive and diagnostic signature.

引用

页数：12

共 36 条

[1] Moesin-dependent cytoskeleton remodelling is associated with an anaplastic phenotype of pancreatic cancer [J].